高危前列腺癌患者根治性前列腺切除术前新辅助177Lu-PSMA-I&T放射性核素治疗:单臂1期试验
这项开放标签单臂1期试验纳入14例高危局限性前列腺癌(HRLPC)且PSMA PET/CT摄取增高的患者,给予2或3剂177Lu-PSMA-I&T(7.4 GBq,间隔2周),末剂后4周行机器人辅助根治性前列腺切除术(RARP)加淋巴结清扫。LuPSMA后行RARP似乎手术安全,肿瘤学结局待定,控尿恢复似乎不受影响。
要点
- 14例高危局限性前列腺癌患者接受新辅助177Lu-PSMA-I&T后行RARP,未发现解剖改变或术中并发症。
- 4例(30%)出现术后并发症:肺炎、肺栓塞、尿漏伴泌尿系感染。
- 术后3个月12例(92%)控尿所需护垫≤1片;7例(53%)切缘阳性。
核心结论
- LuPSMA后行RARP似乎手术安全;肿瘤学结局待定,控尿恢复似乎不受LuPSMA治疗影响。
研究设计与样本
- 开放标签、单臂临床试验;纳入PSMA PET/CT摄取增高的高危局限性前列腺癌患者14例,中位年龄67岁。
- 给予2或3剂LuPSMA(7.4 GBq),间隔2周;末剂后4周行RARP加淋巴结清扫。
- 数据采用描述性分析。
主要发现
- 前列腺特异性抗原在2剂LuPSMA后下降17%(四分位距[IQR] 9-50%),3剂后下降34%(IQR 11-60%)。
- 13例接受RARP,无解剖改变或术中并发症;4例(30%)出现术后并发症(肺炎、肺栓塞、尿漏伴泌尿系感染)。
- 术后3个月12例(92%)所需护垫≤1片;最终全标本病理示7例(53%)切缘阳性,3例(23%)降级至国际泌尿病理学会分级组3。
- 治疗相关效应包括透明空泡状胞质和固缩核。
局限性
- 单臂设计,数据描述性分析,肿瘤学结局待定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-risk localized prostate cancer (HRLPC) has a substantial risk of disease progression despite local treatment. Neoadjuvant systemic therapy before definitive local therapy may improve oncological outcomes by targeting the primary tumor and micrometastatic disease. OBJECTIVE: To evaluate whether a lutetium-177 prostate-specific membrane antigen radioligand (LuPSMA) can be safely administered to patients with HRLPC before robot-assisted radical prostatectomy (RARP) and to describe immediate oncological outcomes. DESIGN, SETTING, AND PARTICIPANTS: This was an open-label, single-arm clinical trial. Patients with HRLPC and elevated radioligand uptake on PSMA positron emission tomography/computed tomography were enrolled. Two or three LuPSMA radioligand doses (7.4 GBq) were given at 2-wk intervals. RARP with lymph node dissection was performed 4 wk after the last LuPSMA dose. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The rate of surgical complications, operative parameters, changes in functional and quality-of-life measures, and immediate oncological outcomes (histological findings and biochemical response) were measured. Data were analyzed descriptively. RESULTS AND LIMITATIONS: Fourteen patients participated (median age 67 yr). Prostate-specific antigen decreased by 17% (interquartile range [IQR] 9-50%) after two LuPSMA doses and 34% (IQR 11-60%) after three doses. Thirteen patients underwent RARP with no identifiable anatomical changes or intraoperative complications. Four patients (30%) had postoperative complications (pneumonia, pulmonary embolism, urinary leak with urinary tract infection). At 3 mo postoperatively, 12 patients (92%) required one pad or less. Final whole-mount pathology showed positive surgical margins (PSMs) in seven patients (53%) and downgrading to International Society of Urological Pathology grade group 3 in three patients (23%). Treatment-related effects included a clear vacuolated cytoplasm and pyknotic nuclei. CONCLUSIONS: LuPSMA followed by RARP appears to be surgically safe. While oncological outcomes are pending, continence recovery seems to be unaffected by LuPSMA treatment. PATIENT SUMMARY: We evaluated outcomes for patients with aggressive localized prostate cancer who received treatment with a radioactive agent before surgical removal of their prostate. This approach appears to be safe and feasible, but its therapeutic efficacy is still unknown.
引用
- Golan S, Frumer M, Zohar Y, et al. Neoadjuvant 177Lu-PSMA-I&T Radionuclide Treatment in Patients with High-risk Prostate Cancer Before Radical Prostatectomy: A Single-arm Phase 1 Trial. Eur Urol Oncol. 2022. PMID: 36216740. doi:10.1016/j.euo.2022.09.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。